GTCbio, San Francisco, CA
09-20 to 09-21-2007
Neurodegenerative diseases such as Alzheimer`s and Parkinson`s disease and conditions such as stroke disrupt the quality of life for patients, extracts an enormous emotional and physical strain on caregivers, and cost society billions of dollars annually. Increasing numbers of elderly people in the population has resulted in a sharp increase in the prevalence of these neurological conditions. Underlying a majority of these disorders is the abnormal degeneration of neurons. In most instances, the etiological causes are unknown and they have a progressive development. While symptomatic treatments are available for many neurodegenerative disorders, drugs to reduce or prevent the neuronal loss in patients have yet to be identified. Intense research over the past few years has generated a rich and complex body of information about the mechanisms and pathophysiology of neurodegenerative conditions. This knowledge has provided the opportunity to find novel targets for drug development and resulting in the initiation of several promising clinical trials.The conference focuses on the latest and most exciting research findings in the identification of novel molecular targets and the development of potential therapeutic strategies for neurodegenerative conditions. In the 1st and 2nd annual conferences, we have had excellent list of speakers from academia, industry and government whose presentations covered a range of topics within the area of neurodegeneration and therapy and with information from cell culture models to clinical trials. The 3rd annual conference will take place on Thursday, Sept 20 and Friday, Sept 21 in San Francisco, California. Please bring this conference to the attention of your colleagues who may benefit from attending the meeting. Please register early and submit an abstract. It is our pleasure to welcome you to the 3rd annual conference on Therapeutic Strategies against Neurodegenerative Conditions in San Francisco.
|
|
Invited Speakers:
|
|
Eric Karran [Keynote Speaker] Chief Scientific Officer, Neurodegenerative Diseases Drug Hunting Team Eli Lilly & Co. Marcelle Bergeron Principal Scientist, Department of Neuroscience Amgen J. Steven Jacobsen Associate Director, Neuroscience Discovery Wyeth Research Jennifer Johnston Principal Scientist Elan Pharmaceuticals Grant Kraft Chairman and Chief Science Officer Acumen Pharmaceuticals, Inc. Jinhe Li Neuroscience Research Abbott Laboratories Ambreena Siddiq Neuroprotection Research Laboratory Burke-Cornell Medical Research Institute James Simpkins Professor and Department Chair University of North Texas Health Science Center Frank La Ferla Co-Director Institute for Brain Aging and Dementia Robert Freeman Associate Professor, Director, Interdepartmental Graduate Program in Neuros University of Rochester School of Medicine Peter H. Reinhart, Ph.D. Senior Director, Neurodegeneration Wyeth Research Manisha Patel University of Colorado Health Sciences Center Massimiliano Bianchi MAPREG Brett Langley Burke-Cornell Medical Research Institute David Lowe CSO, Memory Pharmaceuticals Corporation Santosh R. D'Mello Professor, University of Dallas Jacqueline Kirchner Principal Scientist, Amgen Joseph D. Buxbaum Mount Sinai School of Medicine Julie Andersen Professor, Buck Institute for Age Research Michael Weiner ADNI Principal Investigator, University of California, San Francisco Jianhua Zhang University of Alabama at Birmingham Diane Stephenson Associate Research Fellow, Pfizer Seth P. Finklestein, M.D. Chief Executive Officer Biotrofix, Inc. Peter Seubert, Ph.D. Vice President, Neurodegeneration Research Elan Pharmaceuticals Ronald B. Demattos Neuroscience Discovery Research Eli Lilly & Company William H. Frey II, Ph.D. Director, Alzheimer's Research Center Regions Hospital Daniel Figeys Canada Research Chair in Proteomics and Systems Biology University of Ottawa David S. Park, M.D. [Advisor] Associate Professor Ottawa Health Research Institute Ted Dawson [Advisor] Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases Institute for Cell Engineering, Depts of Neurology and Neuroscience Johns Hopkins University School of Medicine Debomoy Lahiri [Advisor] Institute of Psychiatric Research, Department of Psychiatry Indiana University School of Medicine
|
|